Clinical and economic impact of replacing divalproex sodium with valproic acid

American Journal of Health-System Pharmacy

Volumn 54, Issue 15, 1997, Pages 1716-1722

  Cranor, Carole W ^a,d   Sawyer, William T ^b   Carson, Stanley W ^b   Early, John J ^b,c  

^a IL   (United States)

^b University of North Carolina   (United States)

^c Dorothea Dix Hospital   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Administration; Anticonvulsants; Costs; Divalproex sodium; Drug comparisons; Drug use; Epilepsy; Gastrointestinal drugs; Mental retardation facilities; Outcomes; Packaging; Pharmacy and therapeutics committee; Pharmacy, institutional; Prescribing; Substitution; Toxicity; Valproic acid

Indexed keywords

ANTIBIOTIC AGENT; BRONCHODILATING AGENT; FERROUS SULFATE; HEMOGLOBIN; OMEPRAZOLE; PROMETHAZINE; RANITIDINE; SUCRALFATE; VALPROATE SEMISODIUM; VALPROIC ACID;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG COST; DRUG EFFICACY; ECONOMIC ASPECT; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL HEMORRHAGE; HEMATOCRIT; HUMAN; MALE; MENTAL DEFICIENCY; PRESCRIPTION; PRIORITY JOURNAL; SEIZURE; TREATMENT OUTCOME;

EID: 0030877909     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/54.15.1716     Document Type: Article

References (14)

1. Neurology. 1986; 36:1507a-8a. Advertisement.
2. Depakene package insert. North Chicago, IL: Abbott Laboratories; 1995 Feb.
3. Depakote package insert. North Chicago, IL: Abbott Laboratories; 1995 May.
4. United States Pharmacopeial Convention. USP dispensing information: approved drug products and legal requirements. Vol. 3. Taunton, MA: Rand McNally; 1993.
5. Sparrow SS, Balla DA, Cicchetti DV. Vineland Adaptive Behavior Scale: interview edition survey form manual. Circle Pines, MN: American Guidance Service; 1984.
6. Orchard JL, Stramat J, Wolfgang M et al. Upper gastrointestinal tract bleeding in institutionalized mentally retarded adults. Arch Fam Med. 1995; 4(Jan):30-3.
7. Coulter DL, Wu H, Allen RJ. Valproic acid therapy in childhood epilepsy. JAMA. 1980; 244:785-8.
8. Marks WA, Morris MP, Bodensteiner JB et al. Gastritis with valproate therapy. Arch Neurol. 1988; 45:903-5.
9. Smart JR. Divalproex sodium: a cost-effective alternative in long-term care. Consult Pharm. 1995; 10:533.
10. Wilder BJ, Karas BJ, Penry JK et al. Gastrointestinal tolerance of divalproex sodium. Neurology. 1983; 33:808-11.
11. Cloyd JC, Kriel RL, Jones-Saete CM et al. Comparison of sprinkle versus syrup formulations of valproate for bioavailability, tolerance, and preference. J Pediatr. 1992; 120:634-8.
12. Mattson RH, Cramer JA, Williamson MD et al. Valproic acid in epilepsy: clinical and pharmacological effects. Ann Neurol. 1978; 3(1):20-5.
13. Wilder BJ, Ramsay RE, Murphy JV et al. Comparison of valproic acid and phenytoin in newly diagnosed tonic-clonic seizures. Neurology. 1983; 33:1474-6.
14. Klotz U, Schweizer C. Valproic acid in childhood epilepsy: anticonvulsive efficacy in relation to its plasma levels. Int J Clin Pharmacol Ther Toxicol. 1980; 18:461-5.